Anti-Mouse TIM-2 – Purified in vivo GOLD™ Functional Grade

The monoclonal antibody clone RMT2-25 is most commonly used in vivo in mice to functionally block or modulate the TIM-2 (T cell immunoglobulin and mucin-domain containing-2) pathway for immunological research. Its principal applications include:

• Blocking or agonist experiments to examine the role of TIM-2 in T cell activation and regulation.
• Investigating the Th2 immune response, including its involvement in diseases such as allergy, asthma, and various forms of autoimmunity.
• Studying the broader immunoregulatory roles of TIM-2 in murine models.

In summary, RMT2-25 is used in vivo to dissect how TIM-2 modulates immune cell activation, polarization, and disease processes in mouse models of immune-related disorders.

Commonly used antibodies or proteins studied with RMT2-25 (anti-TIM-2) in the literature include other monoclonal antibodies against TIM family members and costimulatory molecules—especially anti-TIM-1 (RMT1-17), anti-TIM-3 (RMT3-23), anti-TIM-4 (RMT4-53), as well as antibodies like anti-IgM and anti-CD40.

Essential context and typical use cases:

• Co-stimulation and B cell activation: RMT2-25 is frequently used alongside anti-IgM, anti-CD40, and IL-4 for stimulating B cells in vitro to assess antibody isotype production, proliferation, and activation.
• TIM family investigations: Since RMT2-25 targets TIM-2, researchers often examine the functional differences by pairing it with antibodies against other TIM family proteins, including TIM-1, TIM-3, and TIM-4.
• Mechanistic studies: RMT2-25 is sometimes combined with antibodies against costimulatory and regulatory molecules to dissect T cell and B cell signaling pathways. Common examples are anti-CD40 (a co-stimulatory molecule for B cell activation) and anti-IgM (to mimic B cell receptor stimulation).

Other relevant experimental reagents:

• Control rat IgG: Used as an isotype and negative control in these studies.
• IL-4: As a cytokine, often added with antibodies in B cell culture assays to assess effects on class switching and proliferation.

Summary of core combinations:

These combinations are commonly reported in studies of B and T cell immunology, especially to analyze signaling pathways governing lymphocyte activation, antibody production, and immune regulation in mouse models.

Clone RMT2-25 is a rat monoclonal antibody that specifically recognizes mouse TIM-2 (T-cell immunoglobulin and mucin domain 2), and its scientific use has yielded several key findings:

• Blocking Activity: RMT2-25 displays a strong ability to block TIM-2 function, showing stronger blocking activity than other clones like RMT2-14.
• Effect on B Cell Function and Antibody Production: Treatment with RMT2-25 (and RMT2-14) enhances the production of IgG2b and IgG3 antibodies in mouse B cells in vitro. This effect correlates with enhanced B cell activation and antibody secretion due to agonistic stimulation of TIM-2 by these mAbs.
• Role in Immune Modulation: TIM-2 is preferentially upregulated in Th2 cells and downregulated in Th1 cells, and acts as a negative regulator of Th2 responses. By targeting TIM-2, RMT2-25 is implicated in modulating Th2-biased immune responses, which are relevant in atopic disease and allergic inflammation.
• Experimental Model Use: RMT2-25 has been used to experimentally exacerbate collagen-induced arthritis (CIA), suggesting that blocking or agonistically modulating TIM-2 can impact disease severity, likely by promoting B cell activity and skewing the antibody isotype profile.
• Specificity: RMT2-25 specifically binds to TIM-2, a molecule expressed on activated lymphocytes, during certain developmental stages (embryogenesis), and in immune regulation contexts.

Summary Table: Key Findings on RMT2-25

In summary, RMT2-25 is most notable for its strong blockade of TIM-2, its effects on enhancing B cell-driven antibody responses, and its experimental use in immune modulation studies involving mouse models.

There is no published data on dosing regimens for clone RMT2-25 in mouse models in the provided search results or in currently accessible authoritative dosing guides. Clone RMT2-25 is a monoclonal antibody against mouse TIM-2, and it is often referenced in commercial antibody catalogues for in vivo use, but these sources do not specify regimen details such as dose, route, frequency, or schedule for different strains or disease models.

Key points from available sources:

• Search results explicitly state that "there is currently no published data on dosing regimens for clone RMT2-25 in mouse models in the provided search results or authoritative dosing guides".
• Related clones such as RMT2-14 are noted to have variable dosing regimens depending on the immune process or disease model, but specific protocols or dosing schedules are not provided.

Context and Guidance:

• For monoclonal antibody studies in mice, dosing is typically tailored according to:
  • The mouse genetic background (immunocompetent vs. immunodeficient)
  • The targeted disease model (e.g., autoimmune, oncology, infectious)
  • Administration route (intraperitoneal, intravenous, intratumoral)
  • Endpoints such as target engagement, pharmacodynamics, and toxicity
• In the absence of published RMT2-25 regimens, researchers often extrapolate starting doses based on similar antibody studies (typically ranging from 1–10 mg/kg, given once to several times weekly in mice), then optimize based on pharmacokinetics and biological effect in pilot studies.

Recommendations if planning experiments:

• Consult the supplier's technical data sheet for suggestions on initial doses and published literature as it becomes available.
• Reference closely related antibodies such as RMT2-14 for approximate guidance, but pilot dosing—along with appropriate controls—remains critical due to differences in antibody pharmacodynamics.

Given the lack of specific published regimens, it is essential to proceed with caution and ensure experimental dosing is guided by animal ethics protocols, pilot data, and pharmacological monitoring.